6.31
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BHC Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$6.48
Aprire:
$6.5
Volume 24 ore:
902.88K
Relative Volume:
0.41
Capitalizzazione di mercato:
$2.34B
Reddito:
$9.47B
Utile/perdita netta:
$-178.00M
Rapporto P/E:
-13.15
EPS:
-0.48
Flusso di cassa netto:
$1.01B
1 W Prestazione:
-1.71%
1M Prestazione:
+2.10%
6M Prestazione:
-15.19%
1 anno Prestazione:
-14.50%
Bausch Health Companies Inc Stock (BHC) Company Profile
Nome
Bausch Health Companies Inc
Settore
Telefono
514-744-6792
Indirizzo
2150 ST. ELZEAR BLVD. WEST, QUEBEC, QC
Confronta BHC con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
BHC
Bausch Health Companies Inc
|
6.31 | 2.37B | 9.47B | -178.00M | 1.01B | -0.48 |
![]()
ZTS
Zoetis Inc
|
148.60 | 68.99B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.43 | 46.36B | 30.08B | 710.16M | 4.45B | 0.2182 |
![]()
HLN
Haleon Plc Adr
|
9.60 | 44.74B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.06 | 18.81B | 16.54B | -1.64B | 749.00M | -1.45 |
![]()
UTHR
United Therapeutics Corp
|
292.01 | 13.33B | 2.99B | 1.21B | 1.13B | 25.06 |
Bausch Health Companies Inc Stock (BHC) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-08-02 | Downgrade | Piper Sandler | Neutral → Underweight |
2024-07-10 | Iniziato | Raymond James | Mkt Perform |
2023-09-20 | Aggiornamento | Jefferies | Hold → Buy |
2023-06-16 | Downgrade | TD Cowen | Outperform → Market Perform |
2022-07-29 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
2022-07-29 | Downgrade | Truist | Buy → Hold |
2022-07-28 | Downgrade | JP Morgan | Overweight → Neutral |
2022-06-13 | Ripresa | JP Morgan | Overweight |
2021-03-24 | Downgrade | BofA Securities | Neutral → Underperform |
2021-02-17 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
2021-01-22 | Downgrade | Piper Sandler | Overweight → Neutral |
2020-09-17 | Aggiornamento | BofA Securities | Underperform → Neutral |
2020-08-24 | Reiterato | H.C. Wainwright | Buy |
2020-06-17 | Reiterato | H.C. Wainwright | Buy |
2020-04-24 | Iniziato | Citigroup | Buy |
2020-04-02 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
2020-01-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
2020-01-22 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
2019-12-12 | Aggiornamento | JP Morgan | Neutral → Overweight |
2019-12-02 | Iniziato | Goldman | Neutral |
2019-10-25 | Iniziato | Cowen | Outperform |
2019-09-12 | Iniziato | Guggenheim | Buy |
2019-08-15 | Aggiornamento | TD Securities | Hold → Buy |
2019-07-19 | Iniziato | Wolfe Research | Outperform |
2019-06-11 | Ripresa | Barclays | Overweight |
2019-05-13 | Aggiornamento | JP Morgan | Underweight → Neutral |
2019-03-20 | Iniziato | SunTrust | Buy |
2019-01-02 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
2018-11-05 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
2018-09-13 | Aggiornamento | Piper Jaffray | Underweight → Neutral |
Mostra tutto
Bausch Health Companies Inc Borsa (BHC) Ultime notizie
What analysts say about Bausch Health Companies Inc. stockFree Investment Timing Strategies - Jammu Links News
What drives Bausch Health Companies Inc. stock priceRemarkable growth - Jammu Links News
Is Bausch Health Companies Inc. a good long term investmentPhenomenal returns - Jammu Links News
Best Stock to Buy Right Now: Bausch Health vs Canopy Growth? - The Motley Fool Canada
Bausch Health Faces Patent Drama And Policy Questions This Quarter - Finimize
Bausch Health's Xifaxan Patent Clarity, Policy Commentary in Focus for Q2, RBC Says - MarketScreener
In the Wake of Bausch Health Companies Inc.'s (NYSE:BHC) Latest US$196m Market Cap Drop, Institutional Owners May Be Forced to Take Severe Actions - 富途牛牛
In the wake of Bausch Health Companies Inc.'s (NYSE:BHC) latest US$196m market cap drop, institutional owners may be forced to take severe actions - simplywall.st
Amblyopia Market Growth Expected to See Next Level with Novartis - openPR.com
Bausch Health Companies (BHC) Canada Announces Expanded Availability of CABTREO Gel - Yahoo Finance
Icahn Enterprises shares rise 5.72% intraday after Bausch Health appoints new Chief Accounting Officer. - AInvest
Bausch Health's Strategic Leadership Shift: Steven Lee's Expertise Could Propel Valuation Growth Amid Transformation - AInvest
First-Ever Triple-Combination Acne Treatment CABTREO Expands Access Across Canadian Health Programs - Stock Titan
Bausch Health Names Steven Lee Chief Accounting Officer - MarketScreener
Bausch Health Appoints New Chief Accounting Officer - MarketScreener
Bausch Health Strengthens Finance Team: M&A Expert Steven Lee Takes Chief Accounting Officer Role - Stock Titan
Groundbreaking Triple-Combination Acne Treatment Expands Access Across Canadian Healthcare System - Stock Titan
Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Quebec and Two Federal Programs - Yahoo Finance
Bausch Health's Gastroenterology Business, Salix Pharmaceuticals, Launches Fresh "I Wish I Knew" Campaign to Educate People About Xifaxan(R) (rifaximin) for Adults at Risk of Overt Hepatic Encephalopathy Recurrence - standard-journal.com
First FDA-Approved Drug Xifaxan Unveils Powerful Patient Stories in New Hepatic Encephalopathy Campaign - Stock Titan
SHAREHOLDER ALERT: Potential Recovery for Bausch Health Companies Inc. (BHC) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Bausch Health Companies Reaches Analyst Target Price - Nasdaq
August 22nd Options Now Available For Bausch Health Companies (BHC) - Nasdaq
Stocks In Play: Bausch Health Companies - Barchart.com
Bausch Health to Announce Second Quarter 2025 Results on July 30 - Corsicana Daily Sun
Bausch + Lomb's Dry Eye Campaign: A Strategic Opportunity in Growing Eye Health Markets - AInvest
BHC SEC FilingsBausch Health Companies Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Bausch + Lomb Brief: Closes Upsized 675 Million Euro Senior Secured Notes Offering and Partial Credit Agreement Refinancing - MarketScreener
Fed. Circ. Revives MSN Challenge To Bausch IBS Drug Patent - Law360
Bausch + Lomb Brief: Prices Upsized Senior Secured Notes Offering - MarketScreener
GMS Posts Upbeat Earnings, Joins Coinbase Global, Genworth Financial, Sandisk And Other Big Stocks Moving Higher On Wednesday - Benzinga
Bausch Health ticks higher following large director stock purchase - MSN
John Paulson buying at Bausch Health Companies (BHC) - The Globe and Mail
Bausch Health Companies: Insider Confidence Fuels Undervalued Stock's Turnaround Potential - AInvest
Bausch Health to Participate in the J.P. Morgan Global Leveraged Finance Conference - The Globe and Mail
Director buying at Bausch Health Companies (BHC) - The Globe and Mail
Bausch Health: Repricing Potential Driven By Deleveraging (NYSE:BHC) - Seeking Alpha
Bausch Health Companies Inc. (TSE:BHC) Director John Paulson Acquires 754,134 Shares - MarketBeat
Bausch Health (BHC) Jumps 8.5% as Exec Hikes Stake; Subsidiaries Raise Over $3-Billion Fresh Funds - MSN
LOOK: These 10 Stocks Just Stole The Show - Insider Monkey
Bausch Health (BHC) Rises After Director's $15M Share Purchase - GuruFocus
Bausch Health Companies Stock Price, Quotes and Forecasts | NYSE:BHC - Benzinga
Hedge Fund and Insider Trading News: Philippe Laffont, Warren Buffett, Bill Ackman, Farallon Capital, Bausch Health Companies Inc (BHC), MicroStrategy Inc (MSTR), and More - Insider Monkey
Rising Demand in Traveler's Diarrhea MarketTop Developments, - openPR.com
Oral Proteins & Peptides Market worth US$24.00 billion by 2030 with 22.1% CAGR | MarketsandMarkets™METRO - METRO - NEWS CHANNEL NEBRASKA
Oral Proteins & Peptides Market worth US$24.00 billion by 2030 with 22.1% CAGR | MarketsandMarkets - The Globe and Mail
Benzodiazepine Drugs Market Trends, Growth Forecast, and Top - openPR.com
Bausch + Lomb Launching Senior Secured Notes Offering and Refinancing Credit Agreement - marketscreener.com
Bausch + Lomb Brief: Launching Senior Secured Notes Offering and Refinancing Credit Agreement - marketscreener.com
Huntington's Disease Market Grows with Increased Genetic - openPR.com
Reconstructive Surgery Market Trends, Size & Growth Forecast - openPR.com
Bausch Health Companies Inc Azioni (BHC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):